CircuLite is a company developing a unique circulatory assistance device for the treatment of chronic heart failure. Synergy™, the company’s pocket circulatory assistance device features a micro-pump that is placed superficially and minimally invasively connected to the left atrium and the subclavian artery. Once in place, the device transforms the treatment of chronic heart failure patients, irrespective of whether they are hospitalised or treated as outpatients. The company received CE marking on 5 September 2012 for its Synergy™ device.
Heartware Inc. (Nasdaq: HTW) acquired Circulite in December 2013 for an initial sum of $30 million, potentially rising to $320 million if it hits its milestones.